Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

European stocks remained flat in early trading Wednesday, as gains in healthcare were counterbalanced by a decline in ...

Shares in Google-parent Alphabet (GOOGL, GOOG) tumbled in after-hours trading following the release of the tech giant's ...

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google parent's cloud revenue falls short of estimates, and Advanced Micro Devices ...

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The scrubbing of clinical trial-related pages is notable because of how it could affect the ways researchers both inside and ...